MX2010008740A - Derivado de 3,8-diaminotetrahidroquinolina. - Google Patents

Derivado de 3,8-diaminotetrahidroquinolina.

Info

Publication number
MX2010008740A
MX2010008740A MX2010008740A MX2010008740A MX2010008740A MX 2010008740 A MX2010008740 A MX 2010008740A MX 2010008740 A MX2010008740 A MX 2010008740A MX 2010008740 A MX2010008740 A MX 2010008740A MX 2010008740 A MX2010008740 A MX 2010008740A
Authority
MX
Mexico
Prior art keywords
group
hydrogen atom
carbon atoms
independently represent
alkyl group
Prior art date
Application number
MX2010008740A
Other languages
English (en)
Inventor
Masaaki Nagasawa
Takashi Watanabe
Masaru Terauchi
Kouichirou Tanaka
Masataka Washiduka
Original Assignee
Zeria Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharm Co Ltd filed Critical Zeria Pharm Co Ltd
Publication of MX2010008740A publication Critical patent/MX2010008740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Proveer un compuesto que tiene una actividad agonística potente en GHS-R y que es útil como un agente terapéutico para enfermedades degenerativas sistémicas tal como caquexia; un derivado de 3,8-diaminotetrahidroquinolina representado por la fórmula (1a) (en donde X representa CH2, C=O, CH=OR, CH=SR, o CH-NRR'; m es un número de 1 o 2; Ar representa un grupo fenilo, un grupo naftilo, un grupo heterocíclico aromático de 5 miembros o 6 miembros que tiene uno o dos elementos seleccionados de S, N, y O, o un grupo similar; R1 y R2, que pueden ser idénticos o diferentes uno de otro, cada uno representa un átomo de hidrógeno o un grupo metilo; R3 representa un grupo alquilo de C1 a C6 o un grupo similar; n es un número de 0 o 1; R4 y R5, que pueden ser idénticos o diferentes uno de otro, cada uno representa un átomo de hidrógeno, o un grupo alquilo de C1 a C6, etc., y R6 o R7 R y R' que pueden ser idénticos o diferentes uno con otro, cada uno representa un átomo de hidrógeno o un grupo alquilo de C1 a C6), o su sal. (Ver fórmula I).
MX2010008740A 2008-02-08 2009-02-06 Derivado de 3,8-diaminotetrahidroquinolina. MX2010008740A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008029781 2008-02-08
JP2008277044 2008-10-28
PCT/JP2009/000487 WO2009098901A1 (ja) 2008-02-08 2009-02-06 ３，８－ジアミノテトラヒドロキノリン誘導体

Publications (1)

Publication Number Publication Date
MX2010008740A true MX2010008740A (es) 2010-08-30

Family

ID=40951980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008740A MX2010008740A (es) 2008-02-08 2009-02-06 Derivado de 3,8-diaminotetrahidroquinolina.

Country Status (20)

Country Link
US (2) US8299255B2 (es)
EP (1) EP2241564B1 (es)
JP (1) JP5493870B2 (es)
KR (1) KR101553725B1 (es)
CN (1) CN101939313B (es)
AU (1) AU2009212645B2 (es)
BR (1) BRPI0907749A2 (es)
CA (1) CA2714480C (es)
CY (1) CY1115138T1 (es)
DK (1) DK2241564T3 (es)
ES (1) ES2464342T3 (es)
HR (1) HRP20140449T1 (es)
MX (1) MX2010008740A (es)
PL (1) PL2241564T3 (es)
PT (1) PT2241564E (es)
RU (1) RU2482117C2 (es)
SI (1) SI2241564T1 (es)
TW (1) TWI422585B (es)
WO (1) WO2009098901A1 (es)
ZA (1) ZA201005346B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103328449A (zh) * 2011-01-26 2013-09-25 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
EP2979702A4 (en) 2013-03-25 2016-11-16 Zeria Pharm Co Ltd POSTPRANDIAL GASTROKINETIC AGENT
CN104193722A (zh) * 2014-08-27 2014-12-10 湖南华腾制药有限公司 一种n-叔丁氧羰基-3-甲胺噻吩的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP3817746B2 (ja) 1994-06-20 2006-09-06 株式会社竹屋 パチンコ島台
ES2275313T3 (es) * 1997-08-22 2007-06-01 Kaken Pharmaceutical Co., Ltd. Derivados de amida como promotores de la liberacion de la hormona del crecimiento.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
RU2277092C2 (ru) * 2000-09-15 2006-05-27 Анормед, Инк. Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators

Also Published As

Publication number Publication date
WO2009098901A1 (ja) 2009-08-13
EP2241564A4 (en) 2011-07-20
US20100317693A1 (en) 2010-12-16
CN101939313B (zh) 2013-05-22
AU2009212645A1 (en) 2009-08-13
US8501772B2 (en) 2013-08-06
CN101939313A (zh) 2011-01-05
RU2482117C2 (ru) 2013-05-20
EP2241564A1 (en) 2010-10-20
CA2714480C (en) 2017-03-28
ZA201005346B (en) 2011-11-30
JP5493870B2 (ja) 2014-05-14
US8299255B2 (en) 2012-10-30
BRPI0907749A2 (pt) 2015-07-21
TW200940530A (en) 2009-10-01
JPWO2009098901A1 (ja) 2011-05-26
KR101553725B1 (ko) 2015-09-16
RU2010137336A (ru) 2012-03-20
PT2241564E (pt) 2014-06-12
DK2241564T3 (da) 2014-05-19
AU2009212645B2 (en) 2012-07-19
TWI422585B (zh) 2014-01-11
EP2241564B1 (en) 2014-04-30
CY1115138T1 (el) 2016-12-14
ES2464342T3 (es) 2014-06-02
US20130012537A1 (en) 2013-01-10
KR20100116175A (ko) 2010-10-29
PL2241564T3 (pl) 2014-09-30
HRP20140449T1 (hr) 2014-06-20
CA2714480A1 (en) 2009-08-13
SI2241564T1 (sl) 2014-06-30

Similar Documents

Publication Publication Date Title
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
MY142807A (en) Benzimidazole derivative and use thereof.
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
TW200639158A (en) New compounds with therapeutic effect
TW200519088A (en) Aryl or heteroaryl amide compounds
MX344669B (es) Agente antiplaquetas novedoso.
WO2010013567A1 (ja) アミド誘導体、該アミド誘導体を含有する有害生物防除剤および有害生物の防除方法
EP1724258A4 (en) HETEROARYLPHENYLUREE DERIVATIVE
NZ595260A (en) 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MY145603A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
TW200745034A (en) New compounds
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
WO2009156861A3 (en) Substituted pyrimidone derivatives
MY150269A (en) Novel phenylpyrrole derivative
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
WO2008006625A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
MX2010001566A (es) Derivado de aminopirazolamida.
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
WO2008153042A1 (ja) 抗腫瘍剤
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma

Legal Events

Date Code Title Description
FG Grant or registration